1. Home
  2. AQST vs CTNM Comparison

AQST vs CTNM Comparison

Compare AQST & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aquestive Therapeutics Inc.

AQST

Aquestive Therapeutics Inc.

SELL

Current Price

$3.76

Market Cap

529.4M

Sector

Health Care

ML Signal

SELL

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

SELL

Current Price

$9.57

Market Cap

550.7M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
AQST
CTNM
Founded
2004
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.4M
550.7M
IPO Year
2007
2024

Fundamental Metrics

Financial Performance
Metric
AQST
CTNM
Price
$3.76
$9.57
Analyst Decision
Strong Buy
Buy
Analyst Count
9
8
Target Price
$9.33
★ $21.43
AVG Volume (30 Days)
★ 2.4M
596.9K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 0.46
EPS
★ N/A
N/A
Revenue
★ $67,430,000.00
N/A
Revenue This Year
$11.13
N/A
Revenue Next Year
$40.69
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 0.77
N/A
52 Week Low
$2.94
$6.73
52 Week High
$6.74
$17.79

Technical Indicators

Market Signals
Indicator
AQST
CTNM
Relative Strength Index (RSI) 43.59 46.25
Support Level $3.59 $8.59
Resistance Level $4.34 $13.72
Average True Range (ATR) 0.25 0.77
MACD 0.02 0.23
Stochastic Oscillator 41.85 42.33

Price Performance

Historical Comparison
AQST
CTNM

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: